Gemcitabine in Non-Small Cell Lung Cancer (NSCLC): The Evidence of Its Therapeutic Value in Molecular Age

Clinical Medicine Reviews in Oncology
doi 10.4137/cmro.s5842
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Portico

Related search

162P: Molecular Markers in Advanced Non Small Cell Lung Cancer Patients Receiving Gemcitabine & Cisplatin

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential

Theranostics
MedicineToxicologyPharmaceuticsPharmacology
2013English

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Open Access Journal of Oncology and Medicine
2018English

Combination Studies With Gemcitabine in the Treatment of Non-Small-Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
1998English

Caspase Regulation in Non-Small Cell Lung Cancer and Its Potential for Therapeutic Exploitation

Clinical Cancer Research
Cancer ResearchOncology
2005English

P2.01-129 Potential Impact of KRAS Molecular Profiling of Non-Squamous Non-Small Cell Lung Cancer (NSCLC).

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn120 - Epidemiology and Costs of Non-Small Cell Lung Cancer (Nsclc) in Austria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Metastatic Non-Small-Cell Lung Cancer and the Use of Gemcitabine During Pregnancy

Journal of Perinatology
GynecologyChild HealthPediatricsPerinatologyObstetrics
2008English

Gefitinib in Pretreated Advanced Non-Small Cell Lung Cancer (Nsclc): Analysis of Efficacy

Research in Oncology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy